Citigroup’s Akoya BioSciences AKYA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-931
| Closed | -$1.21K | – | 6063 |
|
|
2025
Q2 | $1.21K | Sell |
931
-18,647
| -95% | -$22.4K | ﹤0.01% | 5394 |
|
|
2025
Q1 | $27.2K | Sell |
19,578
-29,209
| -60% | -$64K | ﹤0.01% | 5026 |
|
|
2024
Q4 | $112K | Buy |
48,787
+29,484
| +153% | +$78.1K | ﹤0.01% | 4778 |
|
|
2024
Q3 | $52.5K | Buy |
19,303
+13,506
| +233% | +$33K | ﹤0.01% | 5010 |
|
|
2024
Q2 | $13.6K | Buy |
5,797
+1,932
| +50% | +$6.16K | ﹤0.01% | 5085 |
|
|
2024
Q1 | $18.1K | Buy |
3,865
+447
| +13% | +$2.32K | ﹤0.01% | 5061 |
|
|
2023
Q4 | $16.7K | Buy |
3,418
+3,399
| +17,889% | +$14.1K | ﹤0.01% | 5043 |
|
|
2023
Q3 | $88 | Sell |
19
-5,397
| -100% | -$31K | ﹤0.01% | 5434 |
|
|
2023
Q2 | $40K | Buy |
+5,416
| New | +$36.2K | ﹤0.01% | 4752 |
|
|
2023
Q1 | – | Sell |
-121
| Closed | -$1.16K | – | 5459 |
|
|
2022
Q4 | $1.16K | Sell |
121
-131
| -52% | -$1.61K | ﹤0.01% | 5370 |
|
|
2022
Q3 | $3K | Sell |
252
-771
| -75% | -$10.2K | ﹤0.01% | 5353 |
|
|
2022
Q2 | $13K | Buy |
1,023
+526
| +106% | +$5.45K | ﹤0.01% | 5219 |
|
|
2022
Q1 | $5K | Sell |
497
-3,146
| -86% | -$36.5K | ﹤0.01% | 5793 |
|
|
2021
Q4 | $56K | Buy |
3,643
+2,745
| +306% | +$35.9K | ﹤0.01% | 5001 |
|
|
2021
Q3 | $13K | Buy |
898
+535
| +147% | +$8.95K | ﹤0.01% | 5395 |
|
|
2021
Q2 | $7K | Buy |
+363
| New | +$7.5K | ﹤0.01% | 5761 |
|
Citigroup's AKYA Position: Q3 2025 in Review
Citigroup sold out of Akoya BioSciences (AKYA) in Q3 2025, closing a stake of 931 shares — an estimated $1.21K sold.
Citigroup first reported a position in AKYA in Q2 2021 and held it in 16 quarters. The position peaked at $112K in Q4 2024. 0 funds tracked by Wall St. Rank hold AKYA as of Q3 2025.
- Citigroup reported no remaining Akoya BioSciences position as of Q3 2025 after selling out during the quarter.
- Citigroup sold 931 Akoya BioSciences shares in Q3 2025, an estimated $1.21K.
- Citigroup first reported a position in Akoya BioSciences in Q2 2021 and held it in 16 quarters.
- Citigroup's Akoya BioSciences position peaked at $112K in Q4 2024.
- 0 funds tracked by Wall St. Rank held Akoya BioSciences as of Q3 2025.
Based on Citigroup's 13F filing for Q3 2025, filed 10 Nov 2025.